INTRODUCTION

Infants with acute lymphoblastic leukemia (iALL) comprise a high-risk group with inferior outcome compared with older children. Adverse risk factors include presence of a mixed lineage leukemia (MLL/KMT2A) gene rearrangement (MLL-r), hyperleukocytosis at presentation, age < 90 days at diagnosis and poor response to initial prednisone therapy. Contemporary treatment uses dose-intensive chemotherapy combinations. However, 5-year event-free survival remains < 40% for MLL-r iALL, highlighting the need to identify novel drugs to improve outcome.

Genomic profiling and high-throughput compound screening of patient-derived cell lines have identified personalized treatments in breast and lung cancer and catalogued predictive biomarkers of drug responses across large collections of human cancer cell lines. However, in vitro cancer drug screening is limited by the absence of cell line characterization in relation to the primary disease. For example, over 40 leukemia cell lines have been reported as MLL-r, including mononcitic (for example, MV4-11, MOLM-13, THP-1), immature T-ALL (for example, Karpas 45, SUP-T13) and B-cell precursor ALL (for example, SEM, RS4;11); but there are few reports verifying the molecular representation of cell lines derived from rare clinical sub-types, such as iALL.

We previously demonstrated variable cytotoxic response between two iALL cell lines to contemporary chemotherapeutics highlighting the need to test multiple patient-derived lines. Thus, a panel of genetically characterized cell lines derived from iALL patients with defined clinical features is a crucial resource for drug discovery.

MATERIALS/SUBJECTS AND METHODS

Patient specimens and cell lines

Cell lines were established as described from bone marrow or peripheral blood leukocytes of five infants, diagnosed with iALL at Princess Margaret Hospital for Children, Perth, WA, Australia (Table 1). The Institutional Review Board approved all studies and parental informed consent was obtained.
Table 1. Clinical characteristics of five infants with MLL-rearranged acute lymphoblastic leukemia and characterization of nine patient-derived cell lines

| Patient ID | Sex | Age (days) at diagnosis | White blood count at presentation ($\times 10^9$/l) | CNS status at diagnosis | Upfront therapy | Relapse time from diagnosis to relapse (months) | Relapse therapy | Outcome | Cell line | Doubling time (hours) | Karyotype |
|------------|-----|-------------------------|-----------------------------------------------|------------------------|-----------------|-----------------------------------------------|-----------------|---------|-----------|----------------------|-----------|
| P272       | Female | 339                     | 317                                           | CNS 1                  | CCG 1883        | Bone marrow                                    | CCG 1008        | Died of disease; overall survival 5 months | PER-485A  | 48       | 47, XX, der(4)t(4;11)(q21;q23), add(4)(p16), +6, del(7)(p14), add(8)(q24.3), der(9) inv(9)(p11q12) del(9)(p24), der(11)t(4;11)(q21;q23) |
| P287       | Female | 9                       | 4.2                                           | Unknown               | CCG 1883        | Bone marrow                                    | CCG 0922        | Died of disease; overall survival 4 months | PER-490A  | 72       | 46, XX,t(4;11)(q21;q23)/46,XX,t(4;11),dup(1) q12;q44/46,XX,t(4;11),der(2)t(1;2)(q12;q37); mosaic karyotype. |
| P337       | Female | 82                      | 564                                           | CNS 2                  | CCG 1901-HSCT   | Bone marrow                                    | CCG 1882-2nd HSCT | Alive without disease; 21 years of age at last follow up | PER-784A  | ND       | 46, XX,t(2;11)(q37;q23)/15;ish t(2;11)(3`MLL+;5`MLL+)/10; nuc ish (MLLx2)/5`MLLsep3+MLLx1)/198/200; der(11), der(2) and der(13) in complex rearrangement (FISH). |
| P399       | Female | 66                      | 670                                           | Unknown               | CCG 1953        | No                                             | _               | Alive without disease; 19 years of age at last follow up | PER-785A  | 60       | 46, XX,t(4;11)(q21;q23),der(19)t(1;19)(q12;p13.3)/16;46, i.del(16t(1;16)(q21;q12.1))/46, t(4;11)(3`MLL+;5`MLL+)/5; mosaic karyotype. |
| P810       | Female | 52                      | 102                                           | CNS 2                  | CCG P9407-HSCT  | No                                             | _               | Died from hepatic sinusoidal obstruction syndrome post HSCT; overall survival 4 months | PER-703A  | 60       | 46 ~ 49, XX, +der(1)t(1;11)(p32;q23), t(1;11)(p32;q23), +3, +7, +8, +11 (c[p6]) |

Abbreviations: CCG, Children’s Cancer Group; CNS, central nervous system; COG, Children’s Oncology Group; FISH, fluorescence in situ hybridization; HSCT, hematopoietic stem cell transplantation; MLL, mixed lineage leukemia; ND, not determined.
Pre-treatment patient specimens and cell lines were cultured, unstimulated, for 24 h for cytogenetic analysis. G-banded metaphases and clonal chromosomal abnormalities were reported according to the International System for Human Cytogenetic Nomenclature. Metaphase and interphase fluorescent in situ hybridization analysis was performed using the MLL break apart probe (Abbott Molecular, Des Plaines, IL, USA). Doubling times were determined by absolute cell counts measured by trypan blue exclusion over 10 days. DNA fingerprinting was performed by the Genetic Resources Core Facility at the Johns Hopkins School of Medicine, using the GenePrint 10 kit (Promega, Madison, WI, USA).

RNA-sequence analysis
RNA-seq (100 bp paired end) was performed using the Illumina TruSeq RNA Sample Preparation kit on a HiSeq 2000 (Illumina, Inc., San Diego, CA, USA) at the Australian Genome Research Facility, Melbourne. Raw (fastQ) files were filtered using Trimmomatic and aligned using TopHat21 with a reference annotation GTF from Gencode version (v)19. Gene-counts were generated with HTSeq16 and data were normalized using RUVseq (v1.1.1,17 implementing factor analysis of control genes. 'In-silico' empirical negative control genes were identified by fitting a linear model with grouping of primary and derived cell line data as a covariate. voom18 (limma v3.20.9) was used to normalize for library size. Count data from paired primary and derived cell lines was compared using the Irreproducible Discovery Rate (IDR) package (v1.2) with default settings. Analyses were performed using R (v3.1.2). Gene ontology enrichment analysis was performed using DAVID.20 MLL-fusion split-reads were identified with FusionFinder21 using default settings. Split-reads containing identical strings of MLL- and candidate fusion gene sequences were extracted using 'grep', searching for chimeric sequences with 15 nucleotides flanking the fusion.

In vitro drug sensitivity
In vitro cell viability assays were performed using a modified alamarBlue assay with cells in logarithmic growth. After 72 h drug exposure, alamarBlue fluorescence staining, cells were fixed and permeabilised with 4% formaldehyde and 0.1% Triton-X. Cells were incubated with 2 μl of primary α-Phospho-Histone γ-H2AX rabbit mAb (Cat 9718, Cell Signaling Technology, Danvers, MA, USA) for 20 min; and with 1 μl of secondary goat α-rabbit-FITC for 20 min. PI was added (final concentration 100 μg/ml) before flow cytometric analysis. Cell lysates were prepared for immunoblot using Evans buffer and proteins subject to SDS-PAGE using the NuPage 4–12% Bis-Tris Gel (NP0321, Life Technologies, Carlsbad, CA, USA). Membranes were scanned using the ChemiDoc MP Imaging System (Bio-Rad, Philadelphia, PA, USA).

Drug-response in vivo
Eight-week-old female NOD/SCID mice were inoculated with 1 ×106 PER-785A or PER-826A cells by tail vein injection. Leukemia levels were assessed following inoculation to determine time of reproducible engraftment in bone marrow. Drugs were administered by intraperitoneal injection beginning on day 11 for PER-785A or day 18 for PER-826A xenografts. The potential toxicity of combined administration of ROM and ARAC was assessed with dose-finding experiments by treating NOD/SCID mice with 1 mg/kg ROM twice/week together with graded doses of ARAC (100 mg/kg, 75 mg/kg, 50 mg/kg) three times/week. This revealed that mice receiving the highest ARAC dose showed no overt signs of toxicity assessed by comprehensive monitoring of pain, distress, discomfort, weight gain or weight loss. To determine therapeutic outcome mice were randomized and treated for 3 weeks with either 100 mg/kg ARAC three times/week or 1 mg/kg ROM twice/week or ARAC and ROM combined. Combined ARAC–ROM drug administrations were performed by injecting ROM either 6 or 18 h before ARAC.22 Four days post completion of therapy leukemia burden was assessed by the proportion of human CD19+ positive live cells.

Statistical analysis
Dose-response curves were used to calculate IC50. The area above the dose–response curve (activity area) was determined as described.8 Bar graphs, dot-plots and statistics were generated using GraphPad Prism (v6.0c) with two-sample t-tests or one-way analysis of variance and Tukey’s multiple comparison tests. Synergy was scored using Chalice software (Horizon CombinatorRx Inc., Cambridge, MA, USA), applying the Bliss-independence model.23 Bliss-excess synergy scores were summed across matrices to rank combination effects. Scatterplots and heatmaps were drawn with ggplot2 and hierarchical clustering and correlation analysis were performed in R (v3.1.2).

RESULTS
Establishment and characterization of iALL cell lines
Cell lines were generated from four infant ALL patients diagnosed at <90 days of age and one relapse patient, who was initially diagnosed at 339 days (Table 1). Fluorescence in situ hybridization (FISH) identified the MLL-rearrangement in each patient specimen and matched cell line. G-banded chromosomal analysis revealed sideline clones in cell lines, with structural and numerical changes undetected in patient specimens.12,13,24 DNA fingerprinting revealed identical short tandem repeat profiles for each patient cell line pair except for cell line PER-703A. It lacked a single marker at the THO1 locus on chromosome 11 (Supplementary Table S1), which corresponded with loss-of-heterozygosity of chromosome 11 in this cell line. These results confirmed 100% concordance of DNA markers in cell lines and patient specimens. Immunophenotypic analysis of cell lines revealed a phenotype expressing B-lymphoid (CD19 or CD24) and myeloid (CD33) markers (Table 2). Cell lines PER-784A and PER-826A were also positive for CD7.

Detection of MLL-fusion transcripts
Concordant MLL-fusion partners (Supplementary Table S2) were found for each patient cell line pair. Expression of the reciprocal fusion transcript was detected in two patient samples (P810 (EPS15-MLL) and P399 (AFF1-MLL)) and in each of their matched cell lines. Alternative splice junctions fusing variant MLL exons with partner genes were observed in three patients (P287, P377 and P399), with the same splice variants identified in matched cell lines indicating concordance of MLL-fusion transcripts in iALL cell lines.

Table 2. Immunophenotypes of infant acute lymphoblastic leukemia cell lines

| Cell line | CD7 | CD19 | CD24 | CD33 | CD34 | CD38 | HLA-DR | CD45 |
|-----------|-----|------|------|------|------|------|--------|------|
| PER-485A  | –   | –    | 17%  | 99%  | –    | 24%  | –      | 98%  |
| PER-490A  | –   | 98%  | –    | 52%  | –    | 100% | 94%    | 66%  |
| PER-784A  | 90% | 95%  | 97%  | 65%  | –    | 95%  | 85%    | 99%  |
| PER-826A  | 68% | 97%  | 98%  | 80%  | –    | 99%  | 94%    | 99%  |
| PER-785A  | –   | 99%  | 99%  | 30%  | 80%  | 98%  | 91%    | 99%  |
| PER-785S  | –   | 96%  | 95%  | 49%  | 75%  | 99%  | ND     | 99%  |
| PER-703A  | –   | –    | 98%  | 99%  | –    | 90%  | –      | 98%  |
| PER-703S  | –   | –    | 99%  | 99%  | –    | 95%  | –      | 97%  |
| PER-735S  | –   | –    | 70%  | 94%  | –    | 30%  | 70%    | 92%  |
Comparative transcriptome analysis

The RNA-seq data set comprised 614 million paired end reads, with a median of 47 million read pairs per sample. There were 15,612 expressed genes, defined with a detection cutoff of 75+ reads in two or more of the 13 samples analyzed (five primary and eight cell lines). Using IDR < 0.05, concordant expression was observed in up to 81% of genes (range: 65–81% total transcripts; n = 10,208–12,655; Figure 1a, Supplementary Figure S1A). By intersecting concordantly expressed genes in each cell line and primary sample pairing, we found 8,677 genes (56% of all detectable transcripts), representing the iALL transcriptome with reproducible expression across primary samples and multiple cell cultures. Analysis of gene sets characteristic of hematopoietic progenitors25 revealed similar expression distributions in primary specimens and corresponding cell lines (Supplementary Table S3; Supplementary Figure S1B).

Discordant expression was defined as genes detected in paired samples at levels less than 0.0625 and greater than two counts per million (cpm), revealing 203 genes (1.3% total transcripts) expressed in two or more unrelated cell lines. Using IDR < 0.05, concordant expression was observed in 729 genes (4.7% total transcripts) expressed at lower levels in cell lines relative to patient specimens (Supplementary Figure S1C; Supplementary Table S4). There were 152 genes mapped to Gene Ontology terms (BH adjusted P = 0.37; for example, IL2RA, CD276) and cell signalling (3.1-fold enrichment; BH adjusted P = 0.18; for example, SIGLEC6, PMP22) in contrast, genes at lower levels in cell lines (569 genes mapped to Gene Ontology terms; Supplementary Table S5) are over-represented in immune response (3.0-fold enrichment; BH adjusted P = 1.18 × 10−10; for example, CR1, CR2), antigen-binding (7.9-fold enrichment; BH adjusted P = 3.49 × 10−5; for example, Fc-receptors, immunoglobulins and T-cell receptors) and hematopoietic cell lineage (3.9-fold enrichment; BH adjusted P = 0.04; for example, KIT, CD14, IL1R2) genes.

Gene expression stratified by Ensembl gene-type annotations (n = 15,250) identified 12,130 protein-coding genes (80% of annotated transcripts). Among non-coding (nc) RNA bio-types, processed pseudogenes (n = 922) were the most numerous followed by anti-sense-RNA (n = 915) and long intergenic RNA (n = 556). The set of ncRNAs were consolidated to compare expression of the major RNA bio-types including protein-coding genes, pseudogenes (n = 1261) and other ncRNA genes (n = 1855) (Supplementary Table S6). We found lower expression of ncRNA genes compared with protein-coding genes in primary and matched cell lines, with a similar distribution of the ncRNA bio-types (Figure 1b), consistent with data from normal human tissues.28 When cataloguing conserved in vitro expression across all of the eight cell lines (8,677 annotated genes with IDR < 0.05; Supplementary Table S5), we identified 7,666 protein-coding transcripts, 535 pseudogenes (including 419 processed pseudogenes) and 353 ncRNA (including 190 anti-sense-RNA and 86 long intergenic RNA bio-types). These results reveal similarities in expression of RNA bio-types in primary samples and iALL cell lines.

Effective drug classes comprise inhibitors of proteasome, cyclin-dependent kinase and histone deacetylase.

Our screening strategy focused on identifying novel FDA-approved agents that may also enhance chemotherapeutics. A summary of the initial and secondary screens in Supplementary Figure S2A includes drug information and experimental conditions. The initial screen of 101 FDA-approved cancer drugs (Supplementary Table S7) was performed at three doses, revealing heterogeneity

Figure 1. Comparative analysis of iALL patient and matched cell line transcriptomes. (a) Scatterplots of normalized RNA-seq count data (log2 counts per million) displaying correspondence between patient sample (x axes) and a representative matched cell line (y axes) defined using the IDR algorithm. Data points are coloured according to IDR value. The number of genes showing corresponding expression (below a cutoff IDR < 0.05) for paired samples are shown within each plot. (b) Violinplots displaying RNA-seq count data from patient and matched cell lines partitioned by gene categories defined using Ensembl annotations, including protein-coding genes (n = 12,130), non-coding RNAs (n = 1855) and pseudogenes (n = 1261).
in responses among cell lines (Supplementary Figure S2B). However, we identified proteasome inhibitors and HDACi drug classes that were consistently effective at nanomolar concentrations. We next assessed IC_{50} concentrations on a panel of drugs, including proteasome inhibitors, HDACis, conventional chemotherapeutics and their analogues and rationally chosen targeted inhibitors (Supplementary Figure S2C). These data confirmed variable responses to chemotherapeutics, including dexamethasone, prednisone, ARAC, methotrexate, 6-mercaptopurine, l-asparaginase, thioguanine, etoposide, daunorubicin and 4-hydroxycyclophosphamide. Clofarabine and gemcitabine demonstrated higher efficacy compared with conventional agents within the same drug class (that is, antimetabolites and pyrimidines) used to treat iALL. In accordance with large-scale drug screens, we found consistent efficacy at nanomolar range of vincristine (Figure 2).

Consistent low IC_{50} concentration within nanomolar range, was confirmed for several drugs belonging to proteasome inhibitor and HDACi drug classes. These included three of four proteasome inhibitors, bortezomib (IC_{50} range: 4–10 nM), carfilzomib (3–20 nM) and delanzomib (8–10 nM), with higher IC_{50} doses for MG-132 (0.67–1.25 μM). Two HDACis had consistent nanomolar IC_{50} doses, panobinostat (4–50 nM) and ROM (3–10 nM), with higher IC_{50} doses for vorinostat (0.7–10 μM) and belinostat (0.14–1.1 μM). We also observed nanomolar IC_{50} doses for three of five cyclin-dependent kinase inhibitors. Dinaciclib was the most potent (8–12 nM), followed by flavopiridol (200–350 nM) and SN-302, (213–295 nM). In contrast, PD0332991 was cytotoxic in one cell line, whereas roscovitine was not cytotoxic.

We also identified drugs showing efficacy within micromolar dose range. These included a BCL2-inhibitor, obatoclax (IC_{50} range: 0.2–3.8 μM), and bromodomain and extra-terminal domain family inhibitors, GSK1210151 (0.16–2.4 μM), GSK525762 (0.19–2.1 μM) and JQ1 (0.15–1.35 μM). The JMJD3/UTX H3K27-demethylase inhibitor, GSK-J4, was cytotoxic in four cell lines (1.6–2.3 μM). The EZH2-inhibitor, GSK-343, was not cytotoxic. Drugs targeting receptor tyrosine kinases were generally not cytotoxic, except for lestaurtinib (0.02–1.9 μM) and crizotinib (1.5–3.3 μM).

Conserved in vitro expression of drug target genes
We used RNA-seq data to investigate the expression of drug targets in eight cell lines (Supplementary Table S8). Highly conserved expression (IDR < 0.05; and expression >0.0625 cpm) of targets of chromatin inhibitors was observed in all cell lines, including genes encoding HDACs (HDAC1 to –10; 74/80 reproducible observations), bromodomain and extra-terminal domain family proteins (BRD-2,3,4; 24/24), H3K27-demethylases (JMJD3 and UTX; 16/16) and H3K27-methylases (EZH1 and EZH2; 16/16; Supplementary Figure S3; Supplementary Table S8). We detected 22 transcripts encoding 265 proteasome subunits and five related pseudogenes. Proteasome subunit encoding genes showed broadly conserved expression in cell lines (208/216 reproducible observations; Supplementary Figure S5; Supplementary Table S8), however receptor tyrosine kinase inhibitor targets showed variable expression with only 3/10 receptors (RAF1, BRAF and JAK2) expressed at reproducible levels across the cell line panel (43/75 reproducible observations; Supplementary Figure S6; Supplementary Table S8). Thus, we found broadly concordant in vitro RNA expression of molecules targeted by HDACis, proteasome inhibitors, cyclin-dependent kinase inhibitors and histone H3K27 methylation/demethylation inhibitors and variable expression of receptor tyrosine kinase-encoding genes.

Patient cell line-specific drug interactions
Bortezomib and ROM were the novel drugs chosen for further assessment, owing to their consistent effect in our screen, availability in a formulation suitable for infants and as they have translational potential given they are FDA-approved and undergoing clinical assessment for hematological malignancies. ROM consistently and significantly enhanced the effect of ARAC in five of six cell lines (Figure 3a), reducing the concentration of ARAC required for 50% growth inhibition by 5.9-fold (PER-485A), 4.0-fold (PER-785A), 3.8-fold (PER-826A) 3.1-fold (PER-703A) and 1.5-fold (PER-490A). ROM enhanced dexamethasone efficacy in PER-826A cell line by 1.1-fold and adversely affected dexamethasone cytotoxicity in PER-485A such that 50% growth inhibition was not achieved (Figure 3b). The effects of bortezomib on ARAC and dexamethasone efficacy were variable. Bortezomib enhanced ARAC efficacy in PER-785A (5 nM; 9.5-fold IC_{50} decrease), PER-703A (2 nM; 3.6-fold IC_{50} decrease; 5 nM; 9.7-fold IC_{50} decrease) and PER-826A (2 nM; 7.5-fold IC_{50} decrease). In contrast, bortezomib reduced ARAC efficacy in PER-784A (2 nM; 3.7-fold IC_{50} increase) and had no significant effect on ARAC efficacy in PER-490A or PER-485A (Figure 3a). Bortezomib enhanced the efficacy of dexamethasone in PER-784A (2 nM; 1.4-fold IC_{50} decrease) and in PER-785A (activity area shift from 1.5 (dexamethasone only) to 4.9 (dexamethasone with 5 nM bortezomib)) (Supplementary Figure S7); however, this difference was not captured by IC_{50} change because cell death did not reach 50%. Bortezomib adversely affected the efficacy of dexamethasone in PER-485A such that 50% growth inhibition was not achieved (Figure 3b). These results demonstrate consistent enhancement of ARAC efficacy by ROM with variable effects for other drug combinations. Our results confirm the inverse-correlation between IC_{50} and activity area across all cell lines, with \( r = -0.924 \) (Supplementary Figure S7A–C).

HDAC-inhibitors synergize with ARAC in MLL-r iALL
Combination drug testing in matrix format confirmed that the ARAC–ROM combination provided the strongest synergy in both PER-485A and PER-490A cell lines (Figure 3c), when ranked by the sum of synergy scores. ARAC synergized with ROM and bortezomib in both cell lines at all doses, with ROM showing consistently larger effects (Supplementary Figure S8A–D). In contrast, antagonism was observed with ROM-dexamethasone at several doses in both cell lines (Supplementary Figure S8E and F). The bortezomib–dexamethasone combination, exceeded additive effects in PER-485A, but was antagonistic at higher bortezomib doses (Supplementary Figure S8G-H).

Synergy testing was extended using four different HDACi drugs in an independent MLL-r iALL cell line (PER-826A). We confirmed synergistic interactions at all ARAC–ROM doses tested and also for ARAC-panobinostat, ARAC-mocetinostat and ARAC-LAQ824 combinations with varying magnitudes (Figure 3d). In addition, we examined ARAC–ROM interaction in two pediatric ALL cell lines, of Pre-B and T-cell origin, lacking MLL-r and found additive effects in Pre-B-ALL cells (PER-278 with 1 nM ROM; 1.4-fold ARAC IC_{50} decrease) and antagonistic effects in T-ALL cells (PER-117 with 1 nM ROM; 2.6-fold ARAC IC_{50} increase). Thus, we found ROM enhances ARAC killing in five of six MLL-r iALL cell lines; three additional HDACi drugs capable of enhancing ARAC cytotoxicity; and ROM reduces ARAC efficacy in a germine-MLL T-ALL cell line and enhances ARAC efficacy in a germine-MLL Pre-B-ALL cell line.

ROM modulates cytidine-metabolizing enzymes and ARAC-induced DNA damage–response
Next, we examined the expression of genes and pathways that could mediate the observed ARAC–HDACi combination drug effects (Supplementary Table S7) at steady state, and in perturbation experiments. HDAC-1/-2 repressor complex subunits (Figure 4a) were analyzed, as these are potential targets of ROM, panobinostat and mocetinostat. We detected 22 HDAC-repressor subunits, at a cutoff of 0.0625 cpm. These include seven NuRD subunits, six CoREST subunits, seven SIN3 subunits and two core enzymes (HDAC-1/-2) with highly conserved in vitro expression (175/176
Figure 2. Characterization of drug–responses of iALL cell lines. Response of iALL cell lines to 12 currently used drugs, novel FDA-approved drugs and rationally chosen targeted drugs. Cell viability following 72-h drug exposure was measured by alamarBlue assay. Dose resulting in 50% cell death (IC50) was determined by testing eight drug concentrations (from 3 nM up to 10 μM doses in threefold dilutions). The heatmap shows IC50 values (log10-scale) according to the colour key; cell lines (columns) are ordered by unsupervised clustering. Drugs are ordered according to mechanism of cytotoxicity or chemical structure, with conventional clinical iALL drugs displayed in the top section.

reproducible observations; Figure 4b; Supplementary Table S7). In addition, we examined genes within the ‘cytidine analogue pathway’ involved in ARAC metabolism30 detecting expression of up to 26/32 genes in primary samples (Figure 4c); the majority with conserved expression in vitro (172/201 reproducible observations; Figure 4d; Supplementary Table S7). We subjected the data to cluster analysis focusing on genes within the ‘cytidine analogue pathway’, which revealed separation of cell lines according to ARAC sensitivity (Supplementary Figure S9). DCK was expressed highest in the cell lines most sensitive to ARAC.
ARAC, whereas CDA showed lower expression in the most sensitive cell lines, consistent with reports that ARAC cytotoxicity is limited by lower DCK activity and higher CDA activity.\textsuperscript{31,32} We hypothesized that ARAC–ROM synergy could be mediated by expression of cytidine-metabolizing enzymes and/or alterations to DNA damage–response pathways. We first monitored global histone changes (H3K27-acetylation and H3K79-dimethylation) with time-course experiments and found increases in H3K27-acetylation and H3K79-dimethylation detected at 6 h ROM exposure in iALL cells (data not shown). We next examined kinetics of DCK and CDA, key proteins in the cytidine metabolism pathway in response to ROM. CDA expression was reduced after 2 h incubation with ROM and decreased further at 4, 6 and 8 h (Figures 5a and b; n = 2). In contrast, we did not detect reproducible changes in DCK expression (n = 3). As ARAC induces DNA damage during S-phase\textsuperscript{33,34} we tested whether ROM exposure modulates this response as measured by γ-H2AX and PI (DNA-content) staining in two cell lines with ~16-fold differing ARAC-sensitivities. PER-826A (ARAC IC\textsubscript{50} = 1.7 μM) cells were treated with 5 μM ARAC, and PER-785A (IC\textsubscript{50} = 0.11 μM) were treated with 1 μM ARAC to measure DNA damage after 24 h. Single-agent ROM showed no significant effect on γ-H2AX levels (Figure 5c; ROM vs saline P > 0.05). In contrast, ARAC treatment significantly increased γ-H2AX in all phases of the cell cycle (ARAC vs saline P < 0.0001). Co-dosing with ARAC–ROM induced significant γ-H2AX accumulation in S-phase compared with ARAC in both cell lines (PER-785A P < 0.01, PER-826A P < 0.01) and enhanced γ-H2AX across the cell cycle in PER-826A (G0-G1 P < 0.001, G2-M P < 0.05). Overall, these results reveal highly conserved in vitro expression of genes that could mediate ARAC–ROM interactions, and suggest ROM modulates the expression of cytidine-processing enzymes and enhances the DNA damage–response to ARAC.

Figure 3. ROM synergizes with ARAC in vitro. Cell lines (PER-485A, PER-490A, PER-703A, PER-784A, PER-826A and PER-785A) were treated for 72 h with increasing concentrations of (a) ARAC or (b) dexamethasone in the presence of ROM (1 nM) or bortezomib (2 or 5 nM). Cell viability was measured by alamarBlue and IC\textsubscript{50} values were determined by normalizing to either DMSO controls (for dexamethasone or ARAC only treatment groups) or treatment with ROM or bortezomib only (for co-treated drug groups). Graphs display means of IC\textsubscript{50}, error bars represent 95% confidence intervals and P-values calculated by two-sample t-test (*P < 0.05, **P < 0.01, ***P < 0.001). Drug combinations were evaluated in three replicate experiments; single-agent dexamethasone and ARAC IC\textsubscript{50} were evaluated in six (PER-485A, PER-490A, PER-703A, PER-784A, PER-826A and PER-785A) or nine (PER-703A) replicates. Drug combination effects were not determined (ND) for bortezomib doses causing excessive cell death. (c) PER-485A or PER-490A cells were treated with increasing doses of ARAC or dexamethasone combined with ROM or bortezomib, at a fixed ratio with 1.2-fold incremental differences in drug concentrations. Cell viability was measured by alamarBlue at 72 h and synergy calculated by excess over Bliss. Bar graph displaying the sum of Bliss-excess scores (Bliss Volume) for each drug combination in cell lines PER-485A (green) and PER-490A (yellow). (d) PER-826A cells were treated with ARAC combined with HDACi drugs (ROM, panobinostat, mocetinostat and LAQ824) and synergy determined as described for (c).
Po 0.0001; n = 5) compared with saline, by 15% (3.5–26%; Po 0.01) compared with ROM-only and by 13% (1.6–25%; Po 0.05) compared with ARAC only (Figure 6d). Treatment with ROM 18 h before ARAC (Schedule 2) did not show significant differences compared with saline, or single-agent treated groups in PER-826A xenografts (Figure 6d right panel). Therefore, PER-826A xenografts showed a poor response to ARAC, which could be enhanced by ROM.

**DISCUSSION**

Novel cancer drugs frequently fail to demonstrate the expected benefits when administered to patients, hence the need to review and improve pre-clinical drug screening. 35 Contributing factors include limitations of models used for cancer drug discovery, such as their representation of human disease. 36 A major criticism of cancer cell lines is that they do not fully represent the primary tumor. 37 Although the paradigm of molecular divergence in vitro is accepted, there are few reports comparing genomic profiles of primary specimens and derived cell lines. This is in contrast to patient-derived xenografts, for which several reports have investigated genomic changes following engraftment. 38,39

In this study we focused on MLL-r iALL because of the urgent need for novel therapeutic approaches to improve outcome. We document the genetic and transcriptional landscape of a panel of cell lines and defined over 8000 genes expressed at reproducible levels across eight pairs of cell line/primary samples. This gene set comprised almost 7500 coding and hundreds of non-coding genes (pseudogenes and long non-coding RNAs) and is likely to include essential genes for iALL viability. Importantly, virtually all drug targets from our chemical screen were reproducibly expressed in the iALL cell lines when compared with matched primary specimens. These include targets of HDACis, proteasome inhibitors and cyclin-dependent kinase inhibitors. We also found evidence for multiple MLL-fusion isoforms in three cell lines present in matched primary samples. The MLL-fusion isoforms were due to alternative 5' MLL exon junctions, fused to an invariant 3' partner gene exon suggesting splicing heterogeneity in primary samples and iALL cell lines. Furthermore, we observe conserved in vitro expression of the major RNA bio-types. Altogether, these data support the utility of this panel of iALL cell lines for modelling molecular responses to chemical hits from our screen.
had variable effects on ARAC and dexamethasone efficacy, although combinations of bortezomib and dexamethasone have been effective in other diseases such as multiple myeloma and light-chain amyloidosis. ROM also had variable effects on dexamethasone, suggesting that ROM or bortezomib may not be suitable for co-administration with dexamethasone in some iALL patients. Importantly, we found consistent synergistic enhancement of ARAC by three additional HDACis, supporting HDACs as therapeutic targets to potentiate ARAC killing, consistent with observations in pediatric acute myeloid leukemia.42 The potentiation of ARAC by three HDACis is highly relevant given the current consideration to include HDACis in front-line treatment for iALL patients. Further studies are necessary to determine whether HDACis enhance ARAC in other malignancies treated with these agents such as acute myeloid leukaemia.

Several studies indicate efficacy of drugs targeting chromatin-associated proteins in hematological malignancies.43 By performing an unbiased screen of FDA-approved compounds, we confirmed in vitro sensitivity to a subset of HDACis. Sensitivity to HDACis, including ROM, has previously been reported against t(4;11) MLL-r iALL, whereas sensitivity to HDAC-1/-2 genetic inhibition has also been shown in pediatric B-ALL.44 We also recorded cytotoxic activity of additional agents targeting chromatin features, including three bromodomain and extra-terminal domain family inhibitors within the upper range of doses reported previously in MLL-r AML and the histone H3K27-demethylase inhibitor, GSK-J4, in four cell lines, with an IC50 dose range consistent with responses of T-ALL cells. However, we did not detect growth inhibition activity of the EZH2 H3K27 methylase inhibitor GSK-343, consistent with findings that dual EZH1 and EZH2 inhibition is necessary for anti-leukemic effects in a murine model of MLL-r AML. Taken together, our findings implicate the chromatin landscape as a therapeutic target in MLL-r iALL.

We observed variable efficacy of drugs currently used to treat iALL, with the exception of vincristine. Clofarabine and gemcitabine were more potent than currently used nucleoside analogues of the same respective class. These results emphasize the limitation of contemporary MLL-r iALL chemotherapeutics and indicate the potential of structurally related compounds as noted previously. Importantly, not all of the novel drugs in the three identified classes (HDACis, proteasome inhibitors and cyclin-dependent kinase inhibitors) were efficacious, but those that were effective have demonstrable clinical activity against human hematological malignancies. For example, dinaciclib in relapsed/refractory chronic lymphocytic leukemia and relapsed multiple myeloma; ROM in cutaneous and peripheral T-cell lymphoma; and bortezomib for multiple myeloma and mantle cell lymphoma. The potential benefit of combining chromatin-modifying drugs with currently administered chemotherapeutic drugs is very attractive. Understanding their actions is fundamental to optimizing combination drug therapy. Our studies show that ROM potentiated the action of ARAC by affecting the cytidine-metabolizing pathway. Interestingly, the ARAC-deactivating enzyme, CDA was depleted after 2 h ROM treatment and fell below 20% within 8 h. We demonstrated that ROM also affects the DNA damage–response, and observed significantly increased γ-H2AX over and above the effect of ARAC alone. We noted distinct differences in response patterns in two iALL cell lines, which also differ by a factor of 16 in sensitivity to ARAC. Taken together, the drug effects are evident within hours under in vitro conditions and appear to be dependent on the features of each cell line. These observations are reflected by our xenograft studies, whereby the iALL cell line with a higher in vitro IC50 (PER-826A) showed a poorer response to ARAC treatment in vivo, indicating that in vivo efficacy recapitulates in vitro sensitivity. Furthermore, the two xenograft models showed distinct responses to combined ROM-ARAC treatment. We demonstrated that the enhancing effect of ROM was evident when the drugs were administered 6 h apart, but diminished when...
administered 18 h apart. We conclude from in vitro and in vivo studies that the timing of drug administration is of critical importance, and warrants further optimization. Further studies are required to integrate analyses of chromatin, transcription and protein expression in order to characterize the sequence of changes induced by this drug combination to modulate the DNA damage response and induce cytotoxicity.

In conclusion, we have generated a novel panel of molecularly characterized MLL-r iALL cell lines. Our data using this panel of cell lines showed variable efficacy of several drugs currently used to treat iALL. We have identified several FDA-approved anti-cancer drugs showing cytotoxic effects in MLL-r iALL cells, which are not presently used to treat this aggressive cancer. Our results highlight the clinical potential of drugs targeting chromatin for iALL therapy, in particular the FDA-approved HDACis.

CONFLICT OF INTEREST
RK Prinjha and N Smithers are employees and shareholders of GlaxoSmithKline, which is carrying out clinical development of epigenetic inhibitors. The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by project grants from the Children’s Leukaemia and Cancer Research Foundation, Western Australia and The Kids Cancer Project. Mark N Cruickshank is supported by the Woolworths Children’s Leukaemia and Cancer Research Foundation Fellowship. We thank the patients, families and hospital staff for providing leukemic samples.

REFERENCES
1. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynor PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012; 30: 1663–1669.
2. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240–250.
3. Dreyer ZE, Hildén JM, Jones TL, Devidas M, Winick NJ, Willman CL et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer 2014; 62: 419–426.
4. Kotecha RS, Gottardo NG, Kees UR, Cole CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J 2014; 4: e200.
5. Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol 2011; 29: 214–222.
6. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC et al. Cancer therapy: Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216–220.
7. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346: 1480–1486.
Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Kelly RD, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2.

Caldwell JT, Edwards H, Buck SA, Ge Y, Taub JW. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer 2014; 71: 1677–1733.

Yang C, Boyson CA, Di Liberto M, Huang X, Hannah J, Dorr NC et al. CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity. Cancer Res 2015; 75: 1838–1845.

Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 2013; 30: 648–657.

Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res 2014; 74: 2377–2384.

Herter-Sprie GS, Kung AL, Wong KK. New cast for a new era: preclinical cancer drug development revisited. J Clin Invest 2013; 123: 3639–3645.

Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012; 18: 5314–5328.

Kflo JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL, O’Laughlin M et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014; 25: 379–392.

Painuly U, Kumar S. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol 2013; 7: 53–73.

Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica 2014; 99: 209–221.

Xie C, Edwards H, Xu X, Zhou H, Buck SA, Stout ML et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010; 16: 5499–5510.

Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2013; 373: 1136–1152.

Fong CY, Morisson J, Dawson MA. Epigenetics in the hematologic malignancies. Haematologica 2014; 99: 1772–1783.

Stempel DJ, Schneider P, Selulja L, Osaki H, Williams O, Pieters R et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(11;11)-positive infant acute lymphoblastic leukemia. Leukemia 2012; 26: 682–692.

Stubbs MC, Kim W, Banteau M, Davis T, Vempati S, Minehart J et al. Selective Inhibition of HDAC1 and HDAC2 as a Potential Thespoeus Cspic for B-ALL. Clin Cancer Res 2015; 21: 2348–2358.

Dawson MA, Pinjanka RK, Dittmann A, Giotopoulus G, Bantscheff M, Chan W et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Nature 2011; 478: 529–533.

Ntzischochistos P, Tsirigos A, Weidost GE, Trimarchi T, Bakoigianni S, Xu L et al. Comparing roles of histone 3 lysine 27 dimethyllysine in acute lymphoblastic leukemia. Nature 2014; 514: 513–517.

Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 2015; 125: 346–357.

Stempel DJ, Schneider P, Pieters R, Stam RW. The potential of clotarabine in MLL-rearranged infant acute lymphoblastic leukemia. Eur J Cancer 2015; 51: 2008–2021.

Boze P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin’s lymphoma. Expert Opin Pharmacother 2014; 15: 2443–2459.

Flynn J, Jones L, Johnson AJ, Andritsos L, Maddocks K, Jagielski S et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 2015; 29: 1524–1529.

Kumar SK, LaPlant D, Chng WJ, Zonder J, Callander N, Fonseca R et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 2015; 125: 443–448.

Piekarz RL, Frye R, Prince HM, Kirschenbaum W, Zain J, Allen SL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827–5834.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/